The U.S. Food and Drug Administration has granted approval for application ANDA077697 submitted by Apotex Inc. The approval covers a generic ophthalmic solution of latanoprost (0.005%). The product is listed as discontinued in marketing status. The original submission received approval on March 22, 2011. Subsequent supplemental submissions for labeling were approved on November 28, 2012, and December 17, 2015.
Cập nhật pháp chế5 thg 9, 2026•1 phút đọc
FDA Approves Apotex Latanoprost Ophthalmic Solution (ANDA077697)
The FDA approved Apotex's ANDA077697 for a generic latanoprost ophthalmic solution, with labeling supplements approved in 2012 and 2015.
Tổng hợp bởi đội ngũ PharmaCountry · Nguồn: FDA.gov
Đánh giá
(0)
(0)
(0)
(0)
(0)
Bài viết khác
Xem tất cả bài viếtNghiên cứu & Báo cáo
Global Finished Dosage Manufacturing Landscape 2026
5 thg 10, 2026
Cập nhật pháp chếKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 thg 9, 2026
Phân tíchPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 thg 9, 2026
Để lại đánh giá